{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:00:58Z","timestamp":1780290058402,"version":"3.54.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejim.2026.106738","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:16:50Z","timestamp":1770034610000},"page":"106738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Precision medicine with pioneering RNAi therapeutics in ATTR amyloidosis: from bench to bedside"],"prefix":"10.1016","volume":"148","author":[{"given":"Silvia","family":"Malinverni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Verona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3307-0825","authenticated-orcid":false,"given":"Aldostefano","family":"Porcari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.ejim.2026.106738_bib0001","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"12","key":"10.1016\/j.ejim.2026.106738_bib0002","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. a systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.ejim.2026.106738_bib0003","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ehf2.13606","article-title":"Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery","volume":"9","author":"Porcari","year":"2022","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.ejim.2026.106738_bib0004","article-title":"The evolving landscape of screening, management and treatment strategies of aortic stenosis in ATTR amyloidosis","author":"Porcari","year":"2025","journal-title":"Eur J Intern Med"},{"issue":"17","key":"10.1016\/j.ejim.2026.106738_bib0005","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1177\/2047487319877708","article-title":"Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings","volume":"27","author":"Vergaro","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"10.1016\/j.ejim.2026.106738_bib0006","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamacardio.2024.5221","article-title":"Clinical phenotype and prognosis of asymptomatic patients with transthyretin cardiac amyloid infiltration","volume":"10","author":"Porcari","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.ejim.2026.106738_bib0007","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"10.1016\/j.ejim.2026.106738_bib0008","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.123.066524","article-title":"Clinical and prognostic implications of right ventricular uptake on bone scintigraphy in transthyretin amyloid cardiomyopathy","volume":"149","author":"Porcari","year":"2024","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ejim.2026.106738_bib0009","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/14796678.2025.2591554","article-title":"Navigating the emerging landscape of asymptomatic ATTR-CM: challenges, opportunities and the path ahead","volume":"21","author":"Porcari","year":"2025","journal-title":"Future Cardiol"},{"issue":"4","key":"10.1016\/j.ejim.2026.106738_bib0010","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.ajpath.2011.06.024","article-title":"Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I","volume":"179","author":"Rowczenio","year":"2011","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.ejim.2026.106738_bib0011","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15252\/emmm.201505357","article-title":"A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis","volume":"7","author":"Marcoux","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ejim.2026.106738_bib0012","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2024.01.001","article-title":"Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy","volume":"123","author":"Porcari","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"12","key":"10.1016\/j.ejim.2026.106738_bib0013","first-page":"900","article-title":"Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC\/ANMCO consensus document. edited by the italian cardiac amyloidosis network (RIAC)","volume":"25","author":"Porcari","year":"2024","journal-title":"G Ital Cardiol (Rome)"},{"issue":"6669","key":"10.1016\/j.ejim.2026.106738_bib0014","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"issue":"7089","key":"10.1016\/j.ejim.2026.106738_bib0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature04688","article-title":"RNAi-mediated gene silencing in non-human primates","volume":"441","author":"Zimmermann","year":"2006","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ejim.2026.106738_bib0016","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","article-title":"RNAi therapeutic and its innovative biotechnological evolution","volume":"37","author":"Weng","year":"2019","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.ejim.2026.106738_bib0017","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4137\/OED.S4878","article-title":"Bevasiranib for the treatment of wet, age-related macular degeneration","volume":"2","author":"Garba","year":"2010","journal-title":"Ophthalmol Eye Dis"},{"key":"10.1016\/j.ejim.2026.106738_bib0018","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1752-0509-5-19","article-title":"Modeling RNA interference in mammalian cells","volume":"5","author":"Cuccato","year":"2011","journal-title":"BMC Syst Biol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106738_bib0019","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.106738_bib0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejim.2026.106738_bib0021","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ejim.2026.106738_bib0022","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejim.2026.106738_bib0023","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: state-of-the-art and future perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejim.2026.106738_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.ejim.2026.106738_bib0025","first-page":"109","article-title":"Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis","volume":"23","author":"Butler","year":"2016","journal-title":"Amyloid Int J Exp Clin Investig J Int Soc Amyloidosis"},{"issue":"3","key":"10.1016\/j.ejim.2026.106738_bib0026","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat Biotechnol"},{"issue":"5\u20136","key":"10.1016\/j.ejim.2026.106738_bib0027","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","article-title":"Antisense oligonucleotides: from design to therapeutic application","volume":"33","author":"Chan","year":"2006","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"18","key":"10.1016\/j.ejim.2026.106738_bib0028","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1093\/nar\/gkv920","article-title":"The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA","volume":"43","author":"Vickers","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ejim.2026.106738_bib0029","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.ejim.2026.106738_bib0030","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/jm049167j","article-title":"Fully 2\u2019-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA","volume":"48","author":"Allerson","year":"2005","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.ejim.2026.106738_bib0031","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther"},{"issue":"12","key":"10.1016\/j.ejim.2026.106738_bib0032","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"issue":"8","key":"10.1016\/j.ejim.2026.106738_bib0033","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nbt.3298","article-title":"Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown","volume":"33","author":"Wittrup","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.ejim.2026.106738_bib0034","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1016\/j.ejim.2026.106738_bib0035","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejim.2026.106738_bib0036","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","article-title":"Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications","volume":"203","author":"D\u2019Souza","year":"2015","journal-title":"J Control release J Control Release Soc"},{"issue":"2","key":"10.1016\/j.ejim.2026.106738_bib0037","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1021\/acs.bioconjchem.6b00651","article-title":"Well-defined multivalent ligands for hepatocytes targeting via asialoglycoprotein receptor","volume":"28","author":"Huang","year":"2017","journal-title":"Bioconjug Chem"},{"issue":"21","key":"10.1016\/j.ejim.2026.106738_bib0038","doi-asserted-by":"crossref","first-page":"12388","DOI":"10.1093\/nar\/gkx960","article-title":"Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes","volume":"45","author":"Tanowitz","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.ejim.2026.106738_bib0039","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA designs further improve In vivo performance of GalNAc-siRNA conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ejim.2026.106738_bib0040","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.ejim.2026.106738_bib0041","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of Revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc drugs Ther"},{"issue":"10","key":"10.1016\/j.ejim.2026.106738_bib0042","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","volume":"19","author":"Aimo","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10.1016\/j.ejim.2026.106738_bib0043","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1002\/ejhf.70071","article-title":"Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis","volume":"27","author":"Porcari","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.ejim.2026.106738_bib0044","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.106738_bib0045","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/eurheartj\/ehaf667","article-title":"Transthyretin amyloid cardiomyopathy: from cause to novel treatments","volume":"47","author":"Fontana","year":"2025","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.ejim.2026.106738_bib0046","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.106738_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"issue":"13","key":"10.1016\/j.ejim.2026.106738_bib0048","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ejim.2026.106738_bib0049","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/nat.2020.0852","article-title":"Pharmacodynamic and pharmacokinetic properties of full phosphorothioate small interfering RNAs for gene silencing In vivo","volume":"31","author":"Berk","year":"2021","journal-title":"Nucleic Acid Ther"},{"issue":"13","key":"10.1016\/j.ejim.2026.106738_bib0050","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: first global approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ejim.2026.106738_bib0051","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1007\/s00415-022-11276-8","article-title":"Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update","volume":"269","author":"Brannagan","year":"2022","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.ejim.2026.106738_bib0052","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-024-02008-5","article-title":"Eplontersen: first approval","volume":"84","author":"Nie","year":"2024","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejim.2026.106738_bib0053","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Prim"},{"issue":"1","key":"10.1016\/j.ejim.2026.106738_bib0054","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024323","article-title":"Noncerebral amyloidoses: aspects on seeding, cross-seeding, and transmission","volume":"8","author":"Westermark","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"10.1016\/j.ejim.2026.106738_bib0055","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejim.2026.106738_bib0056","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMc2304584","article-title":"Antibody-associated reversal of ATTR amyloidosis-related cardiomyopathy","volume":"388","author":"Fontana","year":"2023","journal-title":"N Engl J Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526000439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526000439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:14:21Z","timestamp":1780287261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526000439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":56,"alternative-id":["S0953620526000439"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106738","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision medicine with pioneering RNAi therapeutics in ATTR amyloidosis: from bench to bedside","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"106738"}}